Director Marco Brughera filed a Form 144 notice with the SEC on November 13, 2026, disclosing a proposed sale of 20,000 common shares of Fennec Pharmaceuticals Inc. following a stock option exercise.

Key Highlights

  • Proposed seller: Marco Brughera, identified in the filing as a Director of Fennec Pharmaceuticals Inc.
  • Shares proposed for sale: 20,000 common shares, with an aggregate market value of $240,000.00.
  • Source of shares: The securities were acquired on November 13, 2026, through a stock option exercise from the issuer, with payment made in cash.
  • Approximate date of sale: November 13, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, on NASDAQ.
  • Shares outstanding: 35,305,117 common shares outstanding, according to the filing.
  • Prior sales in past 3 months: Brughera sold 15,545 common shares on September 15, 2026, for gross proceeds of $160,069.97.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of June 16, 2026.

Brughera's Proposed Share Sale Under Rule 144 at Fennec Pharmaceuticals

According to the Form 144 notice filed on November 13, 2026, Marco Brughera, a director of Fennec Pharmaceuticals Inc. (NASDAQ:FENC), disclosed a proposed sale of 20,000 common shares with an aggregate market value of $240,000.00. The filing states that the shares were acquired on November 13, 2026, through a stock option exercise from the issuer, with full cash payment made on the same date.

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on NASDAQ. The filing reports that 35,305,117 common shares were outstanding at the time of notice. The notice also indicates that the sale is being conducted in reliance on a written trading plan adopted on June 16, 2026, pursuant to Rule 10b5-1 under the Exchange Act.

The filing further discloses that in the three months prior to this notice, Brughera sold 15,545 common shares on September 15, 2026, generating gross proceeds of $160,069.97. The notice was signed by Marco Maria Brughera, and the filing states that the signer represents no knowledge of material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.

What Was Disclosed

Fennec Pharmaceuticals director Marco Brughera filed a Form 144 on November 13, 2026, proposing to sell 20,000 common shares valued at $240,000.00, acquired via stock option exercise, through Morgan Stanley Smith Barney LLC on NASDAQ, under a Rule 10b5-1 plan adopted June 16, 2026.